Nuclear expression of β-catenin and stem cell markers as potential prognostic indicators in medulloblastoma

Abstract

Nucleopositive β-catenin cases were associated with a favorable outcome on univariate analysis. Both CD15 and CD133 positivity were associated with a worse outcome on univariate analysis.

The Role of CD133+ Cells in a Recurrent Embryonal Tumor with Abundant Neuropil and True Rosettes (ETANTR)

“…A higher proportion of CD133+ cells in medulloblastoma, neuroblastoma, and ganglioneuroblastoma correlated with shorter survival and unfavorable histology (13, 34). Gowda et al (13) analyzed the prevalence and prognostic significance of TSC markers CD133 and CD15 in 60 cases of medulloblastoma. They found 70% of medulloblastomas CD133+, with positivity as high as 17.% of cells (13).…”

“…It suggests that tumorigenic potential is limited to a subpopulation of cells with stem-like properties with the ability to proliferate, self-renew, and differentiate into different lineages. Subpopulations of human brain tumor cells expressing the surface markers CD133, CD15, or nestin have been thought to behave in a “stem-like fashion” and have therefore been cautiously identified as markers for BTICs in select tumor types (13, 19, 28). …”

“…Enhanced CD133 expression has been correlated with poor prognosis and decreased survival in patients with medulloblastoma and neuroblastoma (13, 34). A higher proportion of CD133+ cells in medulloblastoma, neuroblastoma, and ganglioneuroblastoma correlated with shorter survival and unfavorable histology (13, 34). Gowda et al (13) analyzed the prevalence and prognostic significance of TSC markers CD133 and CD15 in 60 cases of medulloblastoma.…”

“…Gowda et al (13) analyzed the prevalence and prognostic significance of TSC markers CD133 and CD15 in 60 cases of medulloblastoma. They found 70% of medulloblastomas CD133+, with positivity as high as 17.% of cells (13). CD133+ cells have also been shown to be resistant to chemotherapy and radiation treatment (25).…”

“…A CD15+ subpopulation has been identified in medulloblastoma and glioblastoma (13, 33). Sixty-seven percent of medulloblastomas are CD15+ (with positivity as high as 17.1% of the population) (13).…”